Search 

Almac Discovery is a research driven drug discovery company dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need (including oncology and CNS), by applying a target class approach. The Almac Discovery business model is to develop preclinical stage assets which are then licenced to pharmaceutical or biotech partners for further development. We also look to collaborate with partners to apply our medicinal chemistry and translational biology expertise to targets of mutual interest. Key research themes include deubiquitinase enzymes and protein drug conjugates.

Arctoris is a tech-enabled drug discovery company headquartered in Oxford and Boston. Arctoris combines its unique automation platform, Ulysses, with advanced computational approaches and a world-class team of seasoned drug hunters to guide and rapidly progress its wholly owned and partnered drug discovery programs in oncology and neurology.

Etcembly’s vision is to decode immune repertoires for health and disease.

The TCR repertoire holds the answers to therapeutics and biomarker information, and Etcembly is assembling the world’s largest health and disease immune database, to revolutionise immunotherapy and personalised therapeutics across all patient groups, globally.

We are pushing the frontiers to explore the intersection between immunology and machine learning.

Evgen is a clinical stage drug development company focussed on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation. 

There is a comprehensive intellectual property package over this technology, covering novel compositions and manufacturing methods. 

Evgen exploits sulforaphane’s activity in three distinct disease-relevant cellular pathways; inhibition of pSTAT3, of importance in controlling cancer metastases, up-regulation of Nrf2, a therapeutic target associated with a broad range of diseases which are characterised by excessive oxidative stress, and inflammation and inhibition of SHP2, a target that has relevance in a number of solid tumours and haematological cancers.

Ingenza is a biotechnology company specialising in the design, development and manufacture of diverse, high-value industrial products and therapeutic-proteins. We exploit synergies between synthetic and evolutionary biology, providing next generation microbial and mammalian manufacturing platforms.

What makes Ingenza unique?

Dynamic teamwork forged from full integration between the in-house molecular biology, fermentation and chemistry teams, boosted by close ties to UK universities, provides the perfect skillsets to expertly guide you through your project. We can support you at any stage of development, from proof of concept to scaled-up manufacture under GMP conditions.

Combining the old and the new

Ingenza’s ethos is all about combining the best tried-and-tested traditional methods, the latest breakthroughs and technologies, and a healthy dose of experience and expertise, to bring refreshing innovation to the development of sustainable and cost-competitive biotechnology.